CN102824346B - 使用10-炔丙基-10-去氮杂氨基蝶呤治疗t细胞淋巴瘤 - Google Patents

使用10-炔丙基-10-去氮杂氨基蝶呤治疗t细胞淋巴瘤 Download PDF

Info

Publication number
CN102824346B
CN102824346B CN201210342831.8A CN201210342831A CN102824346B CN 102824346 B CN102824346 B CN 102824346B CN 201210342831 A CN201210342831 A CN 201210342831A CN 102824346 B CN102824346 B CN 102824346B
Authority
CN
China
Prior art keywords
cell lymphoma
propargyl
treatment
pdx
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CN201210342831.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN102824346A (zh
Inventor
O.A.澳康诺尔
F.西罗特纳克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34971703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102824346(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CN102824346A publication Critical patent/CN102824346A/zh
Application granted granted Critical
Publication of CN102824346B publication Critical patent/CN102824346B/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN201210342831.8A 2004-05-30 2005-05-31 使用10-炔丙基-10-去氮杂氨基蝶呤治疗t细胞淋巴瘤 Expired - Lifetime CN102824346B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US52159304P 2004-05-30 2004-05-30
US60/521,593 2004-05-30
US60/521593 2004-05-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800173160A Division CN1960734A (zh) 2004-05-30 2005-05-31 使用10－炔丙基－10－去氮杂氨基蝶呤治疗t细胞淋巴瘤

Publications (2)

Publication Number Publication Date
CN102824346A CN102824346A (zh) 2012-12-19
CN102824346B true CN102824346B (zh) 2015-04-22

Family

ID=34971703

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201210342831.8A Expired - Lifetime CN102824346B (zh) 2004-05-30 2005-05-31 使用10-炔丙基-10-去氮杂氨基蝶呤治疗t细胞淋巴瘤
CNA2005800173160A Pending CN1960734A (zh) 2004-05-30 2005-05-31 使用10－炔丙基－10－去氮杂氨基蝶呤治疗t细胞淋巴瘤

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2005800173160A Pending CN1960734A (zh) 2004-05-30 2005-05-31 使用10－炔丙基－10－去氮杂氨基蝶呤治疗t细胞淋巴瘤

Country Status (23)

Country Link
US (4) US7939530B2 (https=)
EP (1) EP1750716B1 (https=)
JP (1) JP5005532B2 (https=)
KR (1) KR101189693B1 (https=)
CN (2) CN102824346B (https=)
AT (1) ATE405272T1 (https=)
AU (1) AU2005249516B2 (https=)
BR (1) BRPI0510895A (https=)
CA (1) CA2565968C (https=)
DE (1) DE602005009176D1 (https=)
DK (1) DK1750716T3 (https=)
ES (1) ES2313365T3 (https=)
HR (1) HRP20080569T3 (https=)
ME (1) ME01087B (https=)
MX (1) MXPA06013559A (https=)
NO (1) NO337276B1 (https=)
NZ (2) NZ576849A (https=)
PL (1) PL1750716T3 (https=)
PT (1) PT1750716E (https=)
RS (1) RS50622B (https=)
SI (1) SI1750716T1 (https=)
WO (2) WO2005117891A1 (https=)
ZA (1) ZA200609266B (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
US8263354B2 (en) * 2004-05-30 2012-09-11 Sloan-Kettering Institute For Cancer Research Methods for assessing cancer for increased sensitivity to 10-propargyl-10-deazaaminopterin
US20080188479A1 (en) * 2004-05-30 2008-08-07 Sloan-Kettering Institute For Cancer Research Methods to Treat Cancer with 10-propargyl-10-deazaaminopterin and Methods for Assessing Cancer for Increased Sensitivity to 10-propargyl-10-deazaaminopterin
CA2565968C (en) 2004-05-30 2013-01-08 Sloan-Kettering Institute For Cancer Research Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
KR101335021B1 (ko) 2007-07-31 2013-12-12 액세라인크 게놈 테스트의 용도 및 인지 기능 저하 치료용 케톤성 화합물
US20100248249A1 (en) * 2007-08-17 2010-09-30 Allos Therapeutics, Inc. Methods for Assessing Cancer for Increased Sensitivity to 10-Propargyl-10-Deazaaminopterin by Assessing Egfr Levels
US9901578B2 (en) 2007-08-17 2018-02-27 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
WO2009026234A1 (en) * 2007-08-17 2009-02-26 Allos Therapeutics, Inc. Combination of 10-propargyl-10-deazaaminopterin and erlotinib for the treatment of non-small cell lung cancer
US9125881B2 (en) 2008-07-03 2015-09-08 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
WO2010022277A2 (en) * 2008-08-20 2010-02-25 O'connor Owen A Combination of 10-propargyl-10-deazaaminopterin and bortezomib for the treatment of cancers
US20110190305A1 (en) 2010-02-02 2011-08-04 Allos Therapeutics, Inc. Optically Pure Diastereomers of 10-Propargyl-10-Deazaaminopterin and Methods of Using Same
EP2575466B1 (en) * 2010-06-02 2015-04-08 Allos Therapeutics, Inc. Methods for treating methotrexate-resistant disorders with 10-propargyl-10-deazaaminopterin
US20130178441A1 (en) * 2010-08-10 2013-07-11 Allos Therapeutics, Inc. Methods for Extending Progression-Free Survival using 10-Propargyl-10-Deazaaminopterin
WO2013164856A1 (en) 2012-05-04 2013-11-07 Avra Laboratories Private Limited A process for preparing intermediates of 10-propargyl-10-deazaaminopterin (pralatrexate) synthesis and the intermediates thereof
CN103274943B (zh) * 2013-05-24 2015-01-21 苏州明锐医药科技有限公司 4-[1-(2-丙炔基)-3,4-二氧代正丁基]苯甲酸酯及其制备方法
WO2016205203A1 (en) 2015-06-16 2016-12-22 Spectrum Pharmaceuticals, Inc. Combination therapy using belinostat and pralatrexate to treat lymphoma

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4393064A (en) * 1976-03-05 1983-07-12 Sri International Process and composition for treatment of leukemia and process for preparing the same
US4652533A (en) * 1983-04-28 1987-03-24 Pandex Laboratories, Inc. Method of solid phase immunoassay incorporating a luminescent label
US4843155A (en) * 1987-11-19 1989-06-27 Piotr Chomczynski Product and process for isolating RNA
DE69133095T2 (de) * 1990-11-20 2003-03-27 Dade Behring Marburg Gmbh Cyclosporin-Immunoassay
US5354751A (en) * 1992-03-03 1994-10-11 Sri International Heteroaroyl 10-deazaamino-pterine compounds and use for rheumatoid arthritis
US5981592A (en) * 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6323205B1 (en) * 1996-07-17 2001-11-27 Sloan-Kettering Institute For Cancer Research Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
PT944389E (pt) * 1996-07-17 2008-12-03 Sloan Kettering Inst Cancer Composições purificadas de 10-propargil-10-desaza-aminopterina e métodos para a sua utilização no tratamento de tumores
GB0128510D0 (en) * 2001-11-28 2002-01-23 Novartis Ag Organic compounds
CA2565968C (en) * 2004-05-30 2013-01-08 Sloan-Kettering Institute For Cancer Research Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Activity of a novel anti-folate(PDX,10-propargyl-10-deazaaminopterin) against human lymphoma is superior to methotrexate and correlates with tumor RFC-1 gene expression;WANG E S ET AL;《LEUKEMIA AND LYMPHOMA》;20030601;第44卷(第6期);1027-1035 *
PDX,a novel antifolate with potent in vitro and in vivo activity in non-Hodgkin"s lymphoma;WANG EUNICE S ET AL;《BLOOD》;20011116;第98卷(第11期);612a *

Also Published As

Publication number Publication date
HRP20080569T3 (en) 2008-12-31
US8299078B2 (en) 2012-10-30
RS50622B (sr) 2010-06-30
KR20110081327A (ko) 2011-07-13
WO2005117892A1 (en) 2005-12-15
BRPI0510895A (pt) 2007-11-27
CA2565968A1 (en) 2005-12-15
MXPA06013559A (es) 2007-04-24
US7939530B2 (en) 2011-05-10
AU2005249516A1 (en) 2005-12-15
EP1750716A1 (en) 2007-02-14
EP1750716B1 (en) 2008-08-20
KR101189693B1 (ko) 2012-10-10
CN102824346A (zh) 2012-12-19
WO2005117891A1 (en) 2005-12-15
SI1750716T1 (sl) 2009-06-30
PL1750716T3 (pl) 2009-01-30
US20080058280A1 (en) 2008-03-06
DK1750716T3 (da) 2008-12-08
JP5005532B2 (ja) 2012-08-22
NO337276B1 (no) 2016-02-29
US20100120777A1 (en) 2010-05-13
DE602005009176D1 (de) 2008-10-02
CA2565968C (en) 2013-01-08
AU2005249516B2 (en) 2010-11-18
NZ576849A (en) 2011-03-31
NZ551082A (en) 2009-06-26
ME01087B (me) 2012-12-20
ES2313365T3 (es) 2009-03-01
NO20065971L (no) 2006-12-22
US20050267117A1 (en) 2005-12-01
ZA200609266B (en) 2008-12-31
US20130053391A1 (en) 2013-02-28
CN1960734A (zh) 2007-05-09
ATE405272T1 (de) 2008-09-15
HK1177901A1 (en) 2013-08-30
PT1750716E (pt) 2008-11-04
US7622470B2 (en) 2009-11-24
JP2008501038A (ja) 2008-01-17

Similar Documents

Publication Publication Date Title
US8299078B2 (en) Treatment of T-cell lymphoma using 10-propargyl-10-deazaaminopterin
JP5544165B2 (ja) 血液悪性疾患の処置のための方法および組成物
HU219476B (hu) Eljárás valamely 2'-halo-metilidén-származékot és S-fázisú vagy M-fázisú specifikus daganatellenes szert tartalmazó gyógyszerkészítmények előállítására
JP2007535525A (ja) β−カルボリン誘導体を含有する医薬組成物および癌を処置するためのそれらの使用
US6028071A (en) Purified compositions of 10-propargyl-10-deazaaminopterin and methods of using same in the treatment of tumors
ES2928666T3 (es) Piridinetionas, sus composiciones farmacéuticas y su uso terapéutico para el tratamiento de enfermedades proliferativas, inflamatorias, neurodegenerativas o inmunomediadas
TWI426909B (zh) Radiation therapy enhancer
JP2025523058A (ja) Ｃｌｂ－ｂ阻害剤と追加の治療剤を併用した細胞増殖関連病態の処置
US6323205B1 (en) Combinations of 10-propargyl-10-deazaaminopterin and taxols and methods of using same in the treatment of tumors
PT1604991E (pt) Potenciador do efeito antitumoral e agente antitumoral
WO2023070120A1 (en) Ketoamides for treating malignancy
US20100087398A1 (en) Dihydropyridine derivative for treating cancer or a pre-cancerous condition and other conditions
HK1177901B (en) Treatment of t-cell lymphoma using 10-propargyl-10-deazaaminopterin
KR101189692B1 (ko) 10-프로파르질-10-데아자아미노프테린을 사용하는 ｔ-세포림프종의 치료
WO2025194405A1 (en) Polymorphic smarca inhibitors and uses thereof
CN110314159A (zh) 酪氨酸激酶抑制剂联合治疗肿瘤疾病的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1177901

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1177901

Country of ref document: HK

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20150422